文献速递消化内镜消化道肿瘤与早癌消化道出血

血小板减少和中性粒细胞减少的癌症患者内镜操作的安全性

Safety of endoscopy in cancer patients with thrombocytopenia and neutropenia.
PubMed 文献 · Gastrointest Endosc · 2018-12-11

该研究纳入2010至2015年连续接受内镜操作的癌症患者,评估血小板减少和/或中性粒细胞减少条件下内镜的安全性。结果显示,血小板计数≤50×10^3/μL与出血不良事件风险相关,体能状态差与感染不良事件及30天死亡风险升高相关,而低中性粒细胞计数与感染不良事件未见关联。

要点

  • 血小板计数≤50×10^3/μL与出血不良事件风险相关。
  • 体能状态差与感染不良事件及30天死亡风险升高相关(P<.01)。
  • 低中性粒细胞计数与感染不良事件未见关联。

核心结论

  • 对于血小板计数>50×10^3/μL的癌症患者,内镜操作相对安全。
  • 若难以达到50×10^3/μL,血小板计数≥20×10^3/μL可作为血小板输注的合适阈值。
  • 在无需紧急或必要内镜干预时,决定是否行内镜应考虑患者的功能状态。
  • 操作风险与中性粒细胞计数似乎不影响结局。

研究设计与样本

  • 研究为连续纳入2010年至2015年接受内镜操作的血小板减少和/或中性粒细胞减少的癌症患者。
  • 中性粒细胞减少定义为绝对中性粒细胞计数(ANC)<1000 cells/μL,血小板减少定义为血小板计数<100×10^3/μL。
  • 共纳入588例患者,实施783例次操作;其中608例次在血小板减少条件下进行,675例次在中性粒细胞减少条件下进行,500例次内镜同时存在中性粒细胞减少和血小板减少。
  • 采用单变量和多变量广义估计方程模型评估不良事件(AEs)或死亡风险相关因素。

主要发现

  • 24例患者(4.1%)在操作后1周内发生感染性不良事件,29例(4.9%)发生出血性不良事件。
  • 多变量分析显示,血小板计数≤50×10^3/μL与出血不良事件风险相关。
  • 体能状态差与感染不良事件风险升高相关(P<.01),而低ANC与感染性不良事件未见关联。
  • 体能状态差(P<.01)和血小板计数≤100×10^3/μL(P<.05)与30天死亡风险升高相关。
  • 与操作后血小板计数>20×10^3/μL相比,操作前基线血小板计数≤20×10^3/μL且操作后持续<20×10^3/μL与出血不良事件显著风险相关(P<.01);若操作后血小板计数升至>50×10^3/μL,操作后出血风险大大降低(P<.01)。

临床怎么用

  • 作者认为,对于血小板计数>50×10^3/μL的癌症患者,内镜操作相对安全。
  • 作者认为,若难以达到50×10^3/μL,血小板计数≥20×10^3/μL可作为血小板输注的合适阈值。
  • 作者认为,在无需紧急或必要内镜干预时,决定是否行内镜应考虑患者的功能状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cancer patients are prone to thrombocytopenia and neutropenia, which increase the risk of bleeding and infection. We assessed the safety of endoscopic procedures in cancer patients with thrombocytopenia and/or neutropenia. METHODS: We studied consecutive cancer patients with thrombocytopenia and/or neutropenia who underwent endoscopic procedures from 2010 through 2015. Neutropenia was defined as an absolute neutrophil count (ANC) <1000 cells/μL, and thrombocytopenia as a platelet count <100 × 103/μL. Univariate and multivariate generalized estimating equation models were used to assess factors associated with risk of adverse events (AEs) or death. RESULTS: We identified 588 patients who underwent 783 procedures; 608 procedures were performed in the setting of thrombocytopenia and 675 procedures in the setting of neutropenia. Concurrent neutropenia and thrombocytopenia were recorded in 500 endoscopies. Twenty-four patients (4.1%) experienced infectious AEs, whereas 29 (4.9%) experienced bleeding AEs within 1 week of the procedure. On multivariate analysis, platelet count ≤50 × 103/μL was associated with risk of bleeding AEs. In contrast, poor performance status was associated with increased risk of infection AEs (P < .01). No association was observed between low ANC and infectious AEs. Poor performance status (P < .01) and platelet count ≤100 × 103/μL (P < .05) were associated with increased risk of 30-day mortality. A persistent platelet count <20 × 103/μL after the procedure, with a baseline platelet count of ≤20 × 103/μL before the procedure, was associated with significant risk of bleeding AEs compared with a platelet count >20 × 103/μL after the procedure (P < .01); furthermore, if the platelet count increased to >50 × 103/μL after the procedure, the bleeding risk after the procedure was greatly reduced (P < .01). CONCLUSIONS: Endoscopic procedures are relatively safe in cancer patients with platelet count >50 × 103/μL. Nevertheless, a platelet count of ≥20 × 103/μL could be an appropriate threshold for platelet transfusion if 50 × 103/μL is difficult to achieve. The functional status of the patient, in the absence of the need for urgent or necessary endoscopic interventions, should be considered when deciding whether to perform endoscopy. The risk of procedure and the ANC did not seem to affect the outcomes.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Abu-Sbeih H, Ali FS, Coronel E, et al. Safety of endoscopy in cancer patients with thrombocytopenia and neutropenia. Gastrointest Endosc. 2018. PMID: 30550744. doi:10.1016/j.gie.2018.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。